925456-58-2Relevant academic research and scientific papers
Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity
D'Amico, Derin C.,Aya, Toshi,Human, Jason,Fotsch, Christopher,Chen, Jian Jeffrey,Biswas, Kaustav,Riahi, Bobby,Norman, Mark H.,Willoughby, Christopher A.,Hungate, Randall,Reider, Paul J.,Biddlecome, Gloria,Lester-Zeiner, Dianna,Van Staden, Carlo,Johnson, Eileen,Kamassah, Augustus,Arik, Leyla,Wang, Judy,Viswanadhan, Vellarkad N.,Groneberg, Robert D.,Zhan, James,Suzuki, Hideo,Toro, Andras,Mareska, David A.,Clarke, David E.,Harvey, Darren M.,Burgess, Laurence E.,Laird, Ellen R.,Askew, Benny,Ng, Gordon
, p. 607 - 610 (2007/10/03)
We report the discovery of chroman 28, a potent and selective antagonist of human, nonhuman primate, rat, and rabbit bradykinin B1 receptors (0.4-17 nM). At 90 mg/kg s.c., 28 decreased plasma extravasation in two rodent models of inflammation. A novel met
BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF
-
Page 165, (2008/06/13)
Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and
